Brevan Howard Capital Management’s Nurix Therapeutics NRIX Stock Holding History

Brevan Howard Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-26,501	Closed	-$411K	–	2431
2026 Q1	$411K	Buy	26,501 +5,821	+28%	+$96.5K	﹤0.01%	1424
2025 Q4	$392K	Sell	20,680 -54,104	-72%	-$777K	﹤0.01%	1227
2025 Q3	$691K	Buy	74,784 +11,913	+19%	+$124K	﹤0.01%	1110
2025 Q2	$716K	Buy	+62,871	New	+$679K	﹤0.01%	1215
2025 Q1	–	Sell	-21,495	Closed	-$405K	–	1363
2024 Q4	$405K	Buy	+21,495	New	+$493K	﹤0.01%	683
2024 Q1	–	Sell	-11,068	Closed	-$114K	–	1240
2023 Q4	$114K	Buy	+11,068	New	+$75.9K	﹤0.01%	943

Other funds holding NRIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Brevan Howard Capital Management's NRIX Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Nurix Therapeutics (NRIX) in Q2 2026, closing a stake of 26,501 shares — an estimated $411K sold.

Brevan Howard Capital Management first reported a position in NRIX in Q4 2023 and held it in 6 quarters. The position peaked at $716K in Q2 2025. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

Brevan Howard Capital Management reported no remaining Nurix Therapeutics position as of Q2 2026 after selling out during the quarter.
Brevan Howard Capital Management sold 26,501 Nurix Therapeutics shares in Q2 2026, an estimated $411K.
Brevan Howard Capital Management first reported a position in Nurix Therapeutics in Q4 2023 and held it in 6 quarters.
Brevan Howard Capital Management's Nurix Therapeutics position peaked at $716K in Q2 2025.
211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.